SI-BONE, Inc.

SI-BONE, Inc. (NASDAQ: SIBN) is a medical device company specializing in minimally invasive procedural solutions for compromised bone, with particular expertise in biomechanical design and anatomy-specific innovation. The company pioneered minimally invasive treatment for sacroiliac joint dysfunction and has established a technology platform that extends to thoracolumbar fixation and fusion and pelvic trauma applications. More than 140,000 procedures have been performed using SI-BONE products since the introduction of iFuse in 2009.

The company's product portfolio includes a series of patented titanium implants and associated instruments, as well as implantable bone products. Key offerings include iFuse, iFuse 3D, iFuse TORQ, iFuse Bedrock Granite, iFuse INTRA, and iFuse TORQ TNT. In the United States, these products carry FDA clearances for sacroiliac joint dysfunction, adult spinal deformity, and pelvic trauma applications. In the European Economic Area, select products are CE marked for similar indications. Three of SI-BONE's platform technologies have received FDA Breakthrough Device Designation.

SI-BONE estimates its total addressable market in the United States exceeds $3.5 billion, encompassing sacroiliac joint dysfunction and degeneration, thoracolumbar fixation and fusion, and pelvic trauma. The company's clinical evidence base includes four prospective randomized controlled trials and multiple prospective multicenter studies, with more than 180 publications supporting safety, effectiveness, durability, and economic utility of its implants.

The company operates through a direct sales force and third-party sales agents in the United States and internationally. As of December 31, 2025, the U.S. sales organization consisted of 89 territory sales managers and 83 clinical specialists directly employed by SI-BONE, along with 320 third-party sales agents. International operations included 11 directly employed sales representatives and 28 third-party sales agents operating in 38 countries. SI-BONE's target customer base comprises over 12,000 U.S. physicians, including approximately 7,500 orthopedic and neurological surgeons and 4,500 interventional spine physicians. The company maintains intellectual property protection through 49 issued U.S. patents and 24 pending U.S. patent applications, along with 23 issued foreign patents and 23 pending foreign patent applications. More information is available at www.si-bone.com.